payday loans
wholesale jerseys
Skip to content

Accueil
L'essentiel de la littérature réçente en Pneumologie

Dans cette rubrique on vous propose une revue de la littérature à travers une sélection d'abstracts d'articles originaux.
On essaiera de vous tenir informé des dernières nouveautés de recherche en matière de Pneumologie. On ne vous fournit que le résumé de l'article et le lien correspondant, pour accéder à l'article en full text vous devez être inscrits à la revue correspondante.
Cliquez ici pour consulter la liste des revues de Pneumologie disponibles en libre accès.



Severity scoring systems for pneumonia: current understanding and next steps Imprimer Envoyer
Jeudi, 05 Avril 2018 06:53
imagePurpose of review To describe the current understanding and clinical applicability of severity scoring systems in pneumonia management. Recent findings Severity scores in community-acquired pneumonia are strong markers of mortality, but are not necessarily clinical decision-aid tools. The use of severity scores to support outpatient care in low-risk patients has moderate-to-strong evidence available in the literature, mainly for the pneumonia severity index, and must be applied together with clinical judgment. It is not clear that severity scores are helpful to guide empiric antibiotic treatment. The inclusion of biomarkers and performance status might improve the predictive performance of the well known severity scores in community-acquired pneumonia. We should improve our methods for score evaluation and move toward the development of decision-aid tools. Summary The application of the available evidence favors the use of severity scoring systems to improve the delivery of care for pneumonia patients. The incorporation of new methodologies and the formulation of different questions other than mortality prediction might help the further development of severity scoring systems, and enhance their support to the clinical decision-making process for the pneumonia-management cascade.
Lire la suite...
 
Pneumonia as a systemic illness Imprimer Envoyer
Jeudi, 05 Avril 2018 06:53
imagePurpose of review The manuscript reviews the recent literature describing the occurrence, risk factors, recognition and treatment of sepsis, respiratory failure, and multiple organ dysfunction in patients with community-acquired pneumonia (CAP). Recent findings CAP may present with varying degrees of disease severity ranging from an almost asymptomatic infection to a fulminant systemic disease with both respiratory failure and multiple organ dysfunction. Severe sepsis occurs early in the course of the infection in more than 30% of cases. It may involve several organ systems and is associated with the severity and mortality of CAP. A number of factors exist, which may promote the transition of CAP from a local to a systemic disease, particularly immunosuppression and poorly controlled inflammatory responses, which promote extrapulmonary dissemination of the causative pathogens. Although CAP may be associated with complications involving most organ systems, much recent research has focused attention on cardiac complications, particularly those associated with pneumococcal infections. Biomarkers as a strategy for discriminating between invasive and noninvasive CAP have been comprehensively studied. A number of treatment strategies using antibiotics and various adjunctive therapies have been studied in severe CAP. Summary Recent research highlights the fact that CAP is frequently a systemic illness.
Lire la suite...
 
Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management Imprimer Envoyer
Jeudi, 05 Avril 2018 06:53
imagePurpose of review Multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR)-TB epidemics are key obstacles towards TB control and elimination. Recent findings Diagnosis of MDR/XDR-TB is difficult and requires several weeks. New diagnostic tools are being tested and proposed allowing for shorter time to diagnosis and reduced delays in starting an adequate treatment regimen. MDR/XDR-TB treatment strategies are currently on an evolving stage. New shortened treatments based on the recommended ’Bangladesh regimen’ or on the newer anti-TB drugs, delamanid and bedaquiline may represent part of the future scenario. In addition, more information on safety and efficacy of delamanid and bedaquiline has been published, allowing to better position these drugs. Recent information on treatment regimens for the paediatric age, with or without delamanid or bedaquiline, has become available. This is of great help in designing safer and more efficacious regimens for the treatment of MDR/XDR-TB in children and adolescents. Summary The accessibility, sustainability and scale-up of new diagnostic technologies are lagging behind and more efforts are needed. In addition, we need high-quality information on safety and efficacy of various combinations of drugs to obtain the best possible regimens to treat the largest possible proportion of patients.
Lire la suite...
 
<< Début < Précédent 1 2 3 4 5 6 7 8 9 10 Suivant > Fin >>

Page 3 sur 3337

find-us-on-facebook-2

United4LungHealth

image001

World Allergy Week 2017 The Agony of Hives

WCOPDday2017



PubMed Logo
Word

 To: 

Langtolang Dictionary

CNP2017

50x50_firefoxsafari_iconGchrome

Notre site est optimisé pour les Navigateurs suivants : Firefox, Safari et Google Chrome. Cliquez sur l'un des logos ci-dessus pour le télécharger et l'installer gratuitement.

Tabac

Accueil Top